Claims for Patent: 10,669,236

Summary for Patent: 10,669,236

Title:	Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Abstract:	The present application provides solid Forms A, B, and C of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same. The compounds disclosed herein may be used in the treatment or prevention of a disease or condition in which a tyrosine kinase plays a role.
Inventor(s):	Smolinski; Michael P. (Amherst, NY)
Assignee:	Athenex HK Innovative Limited (Sha Tin, HK)
Application Number:	16/124,281
Patent Claims:	1. A Form B polymorph of Compound A: ##STR00003## characterized by having X-ray powder diffraction peaks at approximately 6.4, 19.3, and 19.9 .degree.2.theta. using Cu K.alpha. radiation. 2. The Form B polymorph of claim 1, characterized by having X-ray powder diffraction peaks at approximately 6.4, 7.2, 19.3, 19.9, 21.6, 22.1, and 22.6 .degree.2.theta. using Cu K.alpha. radiation. 3. The Form B polymorph of claim 1, characterized by having an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1, 6, 8, 10, 15, or 20. 4. The Form B polymorph of claim 1, characterized by an endothermic event with onset at between approximately 133.degree. C. and approximately 138.degree. C. as measured by DSC. 5. The Form B polymorph of claim 1, characterized by a DSC thermogram substantially similar to that set forth in FIG. 16. 6. The Form B polymorph of claim 1, characterized by a weight loss of approximately 0.20% between about 33.degree. C. and about 150.degree. C., as measured by TGA. 7. A pharmaceutical composition comprising a polymorph of claim 1 and a pharmaceutically acceptable carrier or excipient. 8. The Form B polymorph of claim 1, characterized by having X-ray powder diffraction peaks at approximately 6.4, 7.2, 19.3, 19.9, 21.6, 22.1, 22.6, and 24.2 .degree.2.theta. using Cu K.alpha. radiation. 9. The Form B polymorph of claim 1, characterized by having an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 15. 10. The Form B polymorph of claim 1, characterized by an endothermic event with onset at approximately 136.degree. C. as measured by DSC.